Lung cancer is one of the leading causes of cancer-related death worldwide.

Lung cancer is one of the leading causes of cancer-related death worldwide. Despite many advances in medicine, a significant number of patients are still diagnosed at a late stage, having already missed the best window for surgical treatment. These patients are often in poor physical condition and unable to sustain invasive testing procedures.

Cytology smears offer great benefit to these patients, enabling diagnosis, classification, and staging of tumors through minimally invasive approaches by examining pleural effusion and other bodily fluids. Cytopathologists manually observe these smears under microscopes to identify cancer at the cellular level, making precise interpretation essential to patient outcomes.

For late-stage patients who cannot undergo invasive testing, the accuracy and efficiency of cytology screening directly impacts diagnostic outcomes and treatment planning. This underscores the importance of Wellgen's AI-assisted approach to cytology analysis, supporting cytopathologists in identifying cancer at the cellular level with greater speed and consistency—reflecting the company's core mission of "AI-Assisted Diagnosis" for patients who need it most.